Skip to main content

Advertisement

Fig. 1 | Molecular Cancer

Fig. 1

From: Long non-coding RNA SOX2OT promotes the stemness phenotype of bladder cancer cells by modulating SOX2

Fig. 1

Expression of SOX2OT in bladder cancer. a The heights of the columns in the chart represent the log2-transformed fold changes (bladder cancer tissue/normal bladder tissue) in SOX2OT expression in 106 patients with bladder cancer. b SOX2OT is upregulated in bladder cancer tissues compared with in the corresponding non-tumour tissues. c SOX2OT is upregulated in patients with bladder cancer with an advanced TNM stage and a high histological grade. d Higher SOX2OT expression is related to bladder cancer patients’ shorter overall survival (OS) and disease-free survival (DFS) in TCGA-BLCA. e SOX2OT is upregulated in bladder cancer cell lines compared with in the normal urothelial cell line. f BCSCs were isolated from BCCs using flow cytometry based on the stem cell markers CD44 and ALDH1. g SOX2OT and SOX2 expression levels were significantly upregulated in BCSCs compared with in BCNSCs. The data are shown as the mean ± SD. *p < 0.05; **p < 0.01

Back to article page